Cross-talk between non-alcoholic fatty liver disease and cardiovascular disease: implications for future trial design

Ludwig, 1980, Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease, Mayo Clin Proc, 55, 434 Kleiner, 2005, Design and validation of a histological scoring system for nonalcoholic fatty liver disease, Hepatology, 41, 1313, 10.1002/hep.20701 Rinella, 2015, Nonalcoholic fatty liver disease: a systematic review, JAMA, 313, 2263, 10.1001/jama.2015.5370 Min, 2012, Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease, Cell Metab, 15, 665, 10.1016/j.cmet.2012.04.004 Estes, 2018, Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease, Hepatology, 67, 123, 10.1002/hep.29466 Estes, 2018, Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030, J Hepatol, 69, 896, 10.1016/j.jhep.2018.05.036 2018, Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017, Lancet, 392, 1789, 10.1016/S0140-6736(18)32279-7 Adams, 2005, The natural history of nonalcoholic fatty liver disease: a population-based cohort study, Gastroenterology, 129, 113, 10.1053/j.gastro.2005.04.014 Younossi, 2016, Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes, Hepatology, 64, 73, 10.1002/hep.28431 Targher, 2016, Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis, J Hepatol, 65, 589, 10.1016/j.jhep.2016.05.013 Mantovani, 2021, Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals, Gut, 70, 962, 10.1136/gutjnl-2020-322572 Angulo, 2015, Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease, Gastroenterology, 149, 389, 10.1053/j.gastro.2015.04.043 Friedman, 2018, Mechanisms of NAFLD development and therapeutic strategies, Nat Med, 24, 908, 10.1038/s41591-018-0104-9 Cobbina, 2017, Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters, Drug Metab Rev, 49, 197, 10.1080/03602532.2017.1293683 Merrell, 2011, Drug metabolism alterations in nonalcoholic fatty liver disease, Drug Metab Rev, 43, 317, 10.3109/03602532.2011.577781 Spengler, 2015, Recommendations for diagnosis, referral for liver biopsy, and treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, Mayo Clin Proc, 90, 1233, 10.1016/j.mayocp.2015.06.013 Hagström, 2017, Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD, J Hepatol, 67, 1265, 10.1016/j.jhep.2017.07.027 Kleiner, 2019, Association of histologic disease activity with progression of nonalcoholic fatty liver disease, JAMA Netw Open, 2, 10.1001/jamanetworkopen.2019.12565 McPherson, 2015, Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management, J Hepatol, 62, 1148, 10.1016/j.jhep.2014.11.034 Pais, 2013, A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver, J Hepatol, 59, 550, 10.1016/j.jhep.2013.04.027 Feldstein, 2009, Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study, Hepatology, 50, 1072, 10.1002/hep.23050 van Deursen, 2010, Abnormal liver function in relation to hemodynamic profile in heart failure patients, J Card Fail, 16, 84, 10.1016/j.cardfail.2009.08.002 Younossi, 2019, Non-alcoholic fatty liver disease - A global public health perspective, J Hepatol, 70, 531, 10.1016/j.jhep.2018.10.033 Pu, 2019, Diagnostic accuracy of controlled attenuation parameter (CAP) as a non-invasive test for steatosis in suspected non-alcoholic fatty liver disease: a systematic review and meta-analysis, BMC Gastroenterol, 19, 51, 10.1186/s12876-019-0961-9 Saadeh, 2002, The utility of radiological imaging in nonalcoholic fatty liver disease, Gastroenterology, 123, 745, 10.1053/gast.2002.35354 Caussy, 2018, Noninvasive, quantitative assessment of liver fat by MRI-PDFF as an endpoint in NASH Trials, Hepatology, 68, 763, 10.1002/hep.29797 Noureddin, 2013, Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials, Hepatology, 58, 1930, 10.1002/hep.26455 Zhang, 2020, Application of transient elastography in nonalcoholic fatty liver disease, Clin Mol Hepatol, 26, 128, 10.3350/cmh.2019.0001n Bril, 2020, Performance of plasma biomarkers and diagnostic panels for nonalcoholic steatohepatitis and advanced fibrosis in patients with type 2 diabetes, Diabetes Care, 43, 290, 10.2337/dc19-1071 Shah, 2009, Nash Clinical Research Network. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease, Clin Gastroenterol Hepatol, 7, 1104, 10.1016/j.cgh.2009.05.033 2015, ASL-ALEH Clinical Practice Guidelines: non-invasive tests for evaluation of liver disease severity and prognosis, J Hepatol, 63, 237, 10.1016/j.jhep.2015.04.006 Leoni, 2018, Current guidelines for the management of non-alcoholic fatty liver disease: a systematic review with comparative analysis, World J Gastroenterol, 24, 3361, 10.3748/wjg.v24.i30.3361 Chang, 2019, Alcoholic and non-alcoholic fatty liver disease and associations with coronary artery calcification: evidence from the Kangbuk Samsung Health Study, Gut, 68, 1667, 10.1136/gutjnl-2018-317666 Kozlitina, 2020, Genetic risk factors and disease modifiers of nonalcoholic steatohepatitis, Gastroenterol Clin North Am, 49, 25, 10.1016/j.gtc.2019.09.001 VanWagner, 2017, Alcohol use and cardiovascular disease risk in patients with nonalcoholic fatty liver disease, Gastroenterology, 153, 1260, 10.1053/j.gastro.2017.08.012 Ekstedt, 2009, Alcohol consumption is associated with progression of hepatic fibrosis in non-alcoholic fatty liver disease, Scand J Gastroenterol, 44, 366, 10.1080/00365520802555991 Sayiner, 2016, Assessment of health utilities and quality of life in patients with non-alcoholic fatty liver disease, BMJ Open Gastroenterol, 3, 10.1136/bmjgast-2016-000106 Singh, 2015, Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies, Clin Gastroenterol Hepatol, 13, 643, 10.1016/j.cgh.2014.04.014 Schuppan, 2018, Determinants of fibrosis progression and regression in NASH, J Hepatol, 68, 238, 10.1016/j.jhep.2017.11.012 Kim, 2019, Obesity and weight gain are associated with progression of fibrosis in patients with nonalcoholic fatty liver disease, Clin Gastroenterol Hepatol, 17, 543, 10.1016/j.cgh.2018.07.006 Koutoukidis, 2019, Association of weight loss interventions with changes in biomarkers of nonalcoholic fatty liver disease: a systematic review and meta-analysis, JAMA Intern Med, 179, 1262, 10.1001/jamainternmed.2019.2248 Vilar-Gomez, 2015, Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis, Gastroenterology, 149, 367, 10.1053/j.gastro.2015.04.005 Sanyal, 2019, The natural history of advanced fibrosis due to nonalcoholic steatohepatitis: data from the simtuzumab trials, Hepatology, 70, 1913, 10.1002/hep.30664 Siddiqui, 2018, Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science, Hepatology, 67, 2001, 10.1002/hep.29607 Simon, 2017, nonalcoholic steatohepatitis is associated with cardiac remodeling and dysfunction, Obesity (Silver Spring), 25, 1313, 10.1002/oby.21879 Canada, 2019, Relation of hepatic fibrosis in nonalcoholic fatty liver disease to left ventricular diastolic function and exercise tolerance, Am J Cardiol, 123, 466, 10.1016/j.amjcard.2018.10.027 Sanyal, 2006, Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C, Hepatology, 43, 682, 10.1002/hep.21103 Vilar-Gomez, 2018, Fibrosis severity as a determinant of cause-specific mortality in patients with advanced nonalcoholic fatty liver disease: a multi-national cohort study, Gastroenterology, 155, 443, 10.1053/j.gastro.2018.04.034 Sanyal, 2015, Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop, Hepatology, 61, 1392, 10.1002/hep.27678 2018 Merion, 2005, The survival benefit of liver transplantation, Am J Transplant, 5, 307, 10.1111/j.1600-6143.2004.00703.x Siddiqui, 2015, Severity of nonalcoholic fatty liver disease and progression to cirrhosis are associated with atherogenic lipoprotein profile, Clin Gastroenterol Hepatol, 13, 1000, 10.1016/j.cgh.2014.10.008 Bril, 2016, Hepatic steatosis and insulin resistance, but not steatohepatitis, promote atherogenic dyslipidemia in NAFLD, J Clin Endocrinol Metab, 101, 644, 10.1210/jc.2015-3111 Loomba, 2021, Mechanisms and disease consequences of nonalcoholic fatty liver disease, Cell, 184, 2537, 10.1016/j.cell.2021.04.015 Lonardo, 2020, History of nonalcoholic fatty liver disease, Int J Mol Sci, 21, 5888, 10.3390/ijms21165888 Wang, 2004, Impact of obesity on plasma natriuretic peptide levels, Circulation, 109, 594, 10.1161/01.CIR.0000112582.16683.EA Johansen, 2019, Low N-terminal pro-brain natriuretic peptide levels are associated with non-alcoholic fatty liver disease in patients with type 2 diabetes, Diabetes Metab, 45, 429, 10.1016/j.diabet.2018.11.003 Lazo, 2015, The association of liver enzymes with biomarkers of subclinical myocardial damage and structural heart disease, J Hepatol, 62, 841, 10.1016/j.jhep.2014.11.024 Byrne, 2020, NAFLD as a driver of chronic kidney disease, J Hepatol, 72, 785, 10.1016/j.jhep.2020.01.013 Polyzos, 2017, Effects of combined low-dose spironolactone plus vitamin E vs vitamin E monotherapy on insulin resistance, non-invasive indices of steatosis and fibrosis, and adipokine levels in non-alcoholic fatty liver disease: a randomized controlled trial, Diabetes Obes Metab, 19, 1805, 10.1111/dom.12989 Athyros, 2017, The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement, Metabolism, 71, 17, 10.1016/j.metabol.2017.02.014 Nakade, 2017, Ezetimibe for the treatment of non-alcoholic fatty liver disease: a meta-analysis, Hepatol Res, 47, 1417, 10.1111/hepr.12887 Theocharidou, 2018, The Role of PCSK9 in the pathogenesis of non-alcoholic fatty liver disease and the effect of PCSK9 inhibitors, Curr Pharm Des, 24, 3654, 10.2174/1381612824666181010123127 Fontes-Carvalho, 2021, Protective effects of SGLT-2 inhibitors across the cardiorenal continuum: two faces of the same coin, Eur J Prev Cardiol, 10.1093/eurjpc/zwab034 Xing, 2020, Effects of sodium-glucose cotransporter 2 inhibitors on non-alcoholic fatty liver disease in patients with type 2 diabetes: a meta-analysis of randomized controlled trials, J Diabetes Investig, 11, 1238, 10.1111/jdi.13237 Kristensen, 2019, Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials [published correction appears in Lancet Diabetes Endocrinol 2020;8(3):e2], Lancet Diabetes Endocrinol, 7, 776, 10.1016/S2213-8587(19)30249-9 Armstrong, 2016, Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study, Lancet, 387, 679, 10.1016/S0140-6736(15)00803-X Newsome, 2021, A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis, N Engl J Med, 384, 1113, 10.1056/NEJMoa2028395 Han, 2019, Rates of and factors associated with placebo response in trials of pharmacotherapies for nonalcoholic steatohepatitis: systematic review and meta-analysis, Clin Gastroenterol Hepatol, 17, 616, 10.1016/j.cgh.2018.06.011 Ferreira, 2020, Use of the win ratio in cardiovascular trials, JACC Heart Fail, 8, 441, 10.1016/j.jchf.2020.02.010 Lonardo, 2021, Perspectives on Precision Medicine Approaches to NAFLD Diagnosis and Management, Adv Ther, 38, 2130, 10.1007/s12325-021-01690-1 Lonardo, 2019, Sex differences in nonalcoholic fatty liver disease: state of the art and identification of research gaps, Hepatology, 70, 1457, 10.1002/hep.30626 Younossi, 2011, Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality, Hepatology, 53, 1874, 10.1002/hep.24268 Sebastiani, 2015, Prognostic value of non-invasive fibrosis and steatosis tools, hepatic venous pressure gradient (HVPG) and histology in nonalcoholic steatohepatitis, PLoS ONE, 10, 10.1371/journal.pone.0128774 Leung, 2017, Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients, Hepatology, 65, 54, 10.1002/hep.28697 Ito, 2019, Utility and limitations of noninvasive fibrosis markers for predicting prognosis in biopsy-proven Japanese non-alcoholic fatty liver disease patients, J Gastroenterol Hepatol, 34, 207, 10.1111/jgh.14448 Rafiq, 2009, Long-term follow-up of patients with nonalcoholic fatty liver, Clin Gastroenterol Hepatol, 7, 234, 10.1016/j.cgh.2008.11.005